Cardiff Oncology, Inc. (CRDF)
1.015
+0.02
(+1.70%)
USD |
NASDAQ |
Aug 25, 10:07
Cardiff Oncology Enterprise Value : 34.30M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 34.30M |
| August 21, 2026 | 26.23M |
| August 20, 2026 | 28.18M |
| August 19, 2026 | 27.44M |
| August 18, 2026 | 26.64M |
| August 17, 2026 | 27.88M |
| August 14, 2026 | 31.90M |
| August 13, 2026 | 33.34M |
| August 12, 2026 | 33.79M |
| August 11, 2026 | 37.86M |
| August 10, 2026 | 36.49M |
| August 07, 2026 | 33.88M |
| August 06, 2026 | 31.73M |
| August 05, 2026 | 31.36M |
| August 04, 2026 | 29.57M |
| August 03, 2026 | 29.92M |
| July 31, 2026 | 24.53M |
| July 30, 2026 | 24.23M |
| July 29, 2026 | 21.42M |
| July 28, 2026 | 21.97M |
| July 27, 2026 | 23.20M |
| July 24, 2026 | 22.58M |
| July 23, 2026 | 23.35M |
| July 22, 2026 | 24.85M |
| July 21, 2026 | 23.48M |
| Date | Value |
|---|---|
| July 20, 2026 | 23.38M |
| July 17, 2026 | 26.22M |
| July 16, 2026 | 25.84M |
| July 15, 2026 | 26.86M |
| July 14, 2026 | 55.67M |
| July 13, 2026 | 58.41M |
| July 10, 2026 | 57.04M |
| July 09, 2026 | 56.36M |
| July 08, 2026 | 51.56M |
| July 07, 2026 | 58.41M |
| July 06, 2026 | 54.99M |
| July 02, 2026 | 52.93M |
| July 01, 2026 | 54.30M |
| June 30, 2026 | 54.99M |
| June 29, 2026 | 41.42M |
| June 26, 2026 | 40.05M |
| June 25, 2026 | 37.32M |
| June 24, 2026 | 40.74M |
| June 23, 2026 | 40.05M |
| June 22, 2026 | 43.47M |
| June 18, 2026 | 37.32M |
| June 17, 2026 | 35.27M |
| June 16, 2026 | 40.74M |
| June 15, 2026 | 51.68M |
| June 12, 2026 | 59.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ocugen, Inc. | 449.04M |
| CytomX Therapeutics, Inc. | 391.40M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.232M |
| Revenue (Quarterly) | 0.104M |
| Total Expenses (Quarterly) | 9.336M |
| EPS Diluted (Quarterly) | -0.1351 |
| Gross Profit Margin (Quarterly) | -113.5% |
| Profit Margin (Quarterly) | -8.88K% |
| Earnings Yield | -58.19% |
| Normalized Earnings Yield | -58.18 |